Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; What makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

Expert Review of Vaccines

Volumn 15, Issue 4, 2016, Pages 509-517

  Whitehead, Stephen S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Dengue; live attenuated dengue vaccine; vaccine attenuation strategies; vaccine efficacy; vaccine immunogenicity; vaccine infectivity

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; TV 003; TV 005; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ANTIBODY;

DENGUE; DENGUE VIRUS; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SINGLE DRUG DOSE; UNITED STATES; VACCINATION; VACCINE PRODUCTION; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; TREATMENT OUTCOME;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); TREATMENT OUTCOME; UNITED STATES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84948763244     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1115727     Document Type: Review

References (27)

1. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science. 1945; 101: 640-642.
2. Burke DS, Nisalak A, Johnson DE., et al. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg. 1988; 38 (1): 172-180.
3. Kliks S. Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness. AIDS Res Hum Retroviruses. 1990; 6 (8): 993-998.
4. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003; 60: 421-467.
5. Sabchareon A, Wallace D, Sirivichayakul C., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012; 380 (9853): 1559-1567.
6. Villar L, Dayan GH, Arredondo-Garcia JL., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2014; 372 (2): 113-123.
7. Capeding MR, Tran NH, Hadinegoro SRS., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384 (9951): 1358-1365.
8. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015; 373 (13): 1195-1206.
9. Weiskopf D, Angelo MA, de Azeredo EL., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013;110(22):E2046-E2053.
10. Weiskopf D, Sette A. T cell immunity to infection with dengue virus in humans. Front Immunol. 2014; 5 (93):1-5.
11. Villar LA, Rivera-Medina DM, Arredondo-Garcia JL., et al. Safety and Immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, Phase II trial in Latin America. Pediatr Infect Dis J. 2013; 32 (10): 1102-1109.
12. Dayan GH, Thakur M, Boaz M., et al. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine. 2013; 31 (44): 5047-5054.
13. Poo J, Galan F, Forrat R., et al. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled Phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011; 30 (1): e9-e17.
14. Morrison D, Legg TJ, Billings CW., et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010; 201 (3): 370-377.
15. Durbin AP, Kirkpatrick BD, Pierce KK., et al. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine. 2011; 29 (42): 7242-7250.
16. Durbin AP, Kirkpatrick BD, Pierce KK., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis. 2013; 207 (6): 957-965.
17. Kirkpatrick BD, Durbin AP, Pierce KK., et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015; 212 (5): 702-710.
18. Whitehead SS, Hanley KA, Blaney JE Jr., et al. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine. 2003; 21 (27-30): 4307-4316.
19. Durbin AP, McArthur JH, Marron JA., et al. rDEN2/4Delta30(ME), A live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin. 2006; 2 (6): 255-260.
20. Durbin AP, Whitehead SS, McArthur J., et al. rDEN4 delta 30, a live attenuated dengue virus Type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005; 191 (5): 710-718.
21. Durbin AP, Kirkpatrick BD, Pierce KK., et al. Evaluation of the safety and immunogenicity of Tetravax-DV, a live attenuated tetravalent dengue vaccine. In: American Society of Tropical Medicine and Hygiene 59th Annual Meeting. Atlanta (GA): American Society of Tropical Medicine and Hygiene; 2010. Abstract 248.
22. Kliks SC, Nimmanitya S, Nisalak A., et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988; 38 (2): 411-419.
23. Halstead SB, Porterfield JS, ORourke EJ. Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am J Trop Med Hyg. 1980; 29 (4): 638-642.
24. Rivino L, Kumaran EA, Thein TL., et al. Virus-specific T lymphocytes home to the skin during natural dengue infection. Sci Transl Med. 2015; 7 (278): 278ra235.
25. Weiskopf D, Angelo MA, Bangs DJ., et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. 2015; 89 (1): 120-128.
26. Gibbons RV, Kalanarooj S, Jarman RG., et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg. 2007; 77 (5): 910-913.
27. Olkowski S, Forshey BM, Morrison AC., et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis. 2013; 208 (6): 1026-1033.